Miyashita, Minoru http://orcid.org/0000-0002-4151-8725
Hattori, Masaya
Takano, Toshimi
Toyama, Tatsuya
Iwata, Hiroji
Article History
Received: 20 December 2019
Accepted: 9 January 2020
First Online: 23 January 2020
Compliance with ethical standards
:
: Minoru Miyashita reports personal fees from Chugai, personal fees from Lilly, personal fees from Eisai, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Taiho, personal fees from Daiichi Sankyo, non-financial support from Kyowa Hakko Kirin, outside the submitted work. Masaya Hattori reports personal fees from Chugai Pharmaceutical, personal fees from Eli Lilly Japan, personal fees from Novartis Pharma, personal fees from AstraZeneca, personal fees from Pfizer Japan, personal fees from Eisai, outside the submitted work. Toshimi Takano reports grants and personal fees from Daiichi-Sankyo, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Eisai, personal fees from Pfizer, personal fees from Eli Lilly, grants from Ono, grants from MSD, grants from Merck Serono, grants from Taiho, grants from Novartis, grants from Chugai, outside the submitted work. Tatsuya Toyama reports grants and personal fees from Chugai, grants and personal fees from Novartis, grants and personal fees from Esai, grants and personal fees from AstraZeneca, personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Taiho, personal fees from Daiichi Sankyo, personal fees from Nippon Kayaku, personal fees from Pfizer, personal fees from Takeda. Hiroji Iwata Dr. Iwata reports grants and personal fees from Chigai, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, from Kyowa Hakko Kirin, from Pfizer, outside the submitted work.